系统综述:低FODMAP饮食对肠易激综合征症状疗效的试验质量
本系统综述检索Pubmed和EMBASE,纳入9项随机对照试验共542例肠易激综合征患者,评估低FODMAP饮食症状疗效试验的质量。所有试验均存在高偏倚风险,盲法领域尤为突出,仅1项为双盲。干预周期2天至6周,仅1项有6个月随访。作者认为试验报告的症状改善可能主要由安慰剂反应驱动。
要点
- 9项随机对照试验共542例,所有试验均存在高偏倚风险,仅1项双盲。
- 干预周期2天至6周,仅1项有6个月随访,缺乏超过6周的随机对照研究。
- 尚无试验评估再引入期效果,症状改善可能主要由安慰剂反应驱动。
核心结论
- 低FODMAP饮食的随机对照试验均存在高偏倚风险,盲法领域尤为突出。
- 该饮食尚无超过6周的随机对照研究,缺乏评估再引入期效果的试验。
- 试验报告的症状改善可能主要由安慰剂反应驱动。
研究设计与样本
- 系统综述,检索Pubmed和EMBASE中报告低FODMAP饮食对肠易激综合征症状效果的随机对照试验。
- 通过评估偏倚风险和试验方法学评价试验质量。
- 共纳入9项随机对照试验,包括542例患者。
主要发现
- 干预周期为2天至6周,1项试验包含6个月随访。
- 3项试验通过提供餐食进行干预,并以高FODMAP含量饮食作为对照。
- 6项试验由营养师进行指导干预,使用了多种对照干预,均已确立的疗效有限。
- 所有试验均存在高偏倚风险领域,盲法领域以高偏倚风险为主,仅1项试验为双盲。
局限性
- 所有试验均存在高偏倚风险。
- 该饮食尚未在超过6周的随机对照环境中进行研究。
- 缺乏评估重要再引入期效果的试验。
- 试验报告的症状改善可能主要由安慰剂反应驱动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The low Fermentable Oligo-, Di- Monosaccharides, and Polyoles (FODMAP) diet is a new treatment option for irritable bowel syndrome (IBS). Experts refer to the diet as supported by high level of evidence, but an evaluation of the quality of trials is lacking. AIM: To provide a systematic review of the quality of trials on the symptomatic effects of the low FODMAP diet for IBS. METHODS: Pubmed and EMBASE were searched for randomised controlled trials (RCTs) reporting effect of the low FODMAP diet on IBS symptoms. The quality of trials was evaluated by estimating risk of bias and assessing trial methodology. RESULTS: Nine RCTs were eligible, including 542 patients. The intervention period was from 2 days to 6 weeks and one trial included a 6-month follow-up. Three trials intervened by providing meals, controlling with a diet high in FODMAP content. In six trials, the intervention was instruction by a dietician and a variety of control interventions were used, all with limited established efficacy. Domains with a high risk of bias were identified for all the trials. High risk of bias dominated domains regarding blinding, with only one trial double-blinded. CONCLUSIONS: The RCTs on the low FODMAP diet are characterized by high risk of bias. The diet has not been studied in a randomised, controlled setting for more than 6 weeks and trials examining the effect of the important reintroduction period are lacking. There is a risk that the symptomatic effects reported in the trials are driven primarily by a placebo response.
引用
- Krogsgaard LR, Lyngesen M, Bytzer P, et al. Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome. Aliment Pharmacol Ther. 2017. PMID: 28440580. doi:10.1111/apt.14065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。